top 100 Pharma Companies ranking, 2023

Values in USD Billion

Rank	Companies	Revenue	% Change (from 2021)	Business Operating income	% Change (from 2021)	Net Income	% Change (from 2021)	Total Assets	% Change (from 2021)	Capital expenditures (CapEx) 2022	% Change (from 2021)	R&D expenses 2022	% Change (from 2021)	Net Pharma/Healthcare Sales	% Change (from 2021)	EBITDA	% Change (from 2021)
1	Pfizer ^[1]	100.33	23.4%	31.40	39.80%	31.37	42.70%	197.21	8.67%	16.27	9.35%	11.43	10.31%	*	*
2	Janssen/ Johnson & Johnson ^[1]	94.94	1.2%	21.73	-4.61%	17.94	-14.07%	187.38	2.94%	12.37	42.50%	14.60	-0.75%	*	*
3	Roche ^[1]	68.60	2.2%	24.04	3.40%	14.64	-6.00%	-	-	-	-	15.23	2.70%	48.29	2.10%
4	Merck ^[1]	59.28	21.7%	16.44	18.48%	14.52	11.27%	35.72	18.03%	4.39	-1.35%	13.55	10.64%	7.84	*	-	-
5	AbbVie ^[1]	58.05	3.3%	18.12	1.08%	11.84	2.50%	138.81	-5.30%	24.94	9.51%	6.51	-5.95%	*	*
6	Bayer ^[1]	54.43	15.0%	7.52	109.10%	4.45	315.00%	133.96	3.90%	3.90	21.10%	7.05	21.40%	20.65	4.90%	6.66	13.60%
7	Novartis ^[1]	50.55	-2.0%	9.20	-21.30%	6.96	-71.00%	117.45	-10.90%	2.79	-13.30%	10.00	-5.00%	*	*
8	Bristol-Myers Squibb ^[1]	46.16	-0.5%	7.71	-4.75%	6.33	-9.54%	96.82	-11.43%	1.12	14.90%	9.51	-6.73%	*	-
9	Sanofi ^[1]	46.12	13.9%	9.12	4.60%	11.09	25.90%	133.64	3.60%	1.71	13.90%	7.19	17.80%	*	*
10	AstraZeneca ^[1]	44.35	18.5%	3.76	255.78%	3.29	2835.70%	96.48	-8.43%	0.50	29.38%	9.76	0.27%	12.14	8.39%	9.24	22%
11	Fresenius Kabi ^[1]	43.81	9.0%	3.56	-20.13%	2.27	-24.90%	81.97	6.19%	1.91	-11.90%	0.93	7.70%	0.25	-	7.30	-0.67%
12	Abbott EPD ^[1]	43.65	1.3%	8.36	-0.75%	6.93	-1.95%	74.44	-1.01%	1.78	-5.73%	2.89	5.32%	3.73	5.34%	-	-
13	Shanghai Pharma Mfg ^[1]	33.64	7.5%	1.31	9.86%	1.01	11.43%	28.73	21.23%	0.43	-27.32%	0.31	6.29%	29.76	7.60%	-	-
14	CR Pharma Segment ^[1]	32.45	7.3%	1.26	17.21%	1.00	17.99%	30.81	-2.93%	0.55	35.07%	0.27	23.75%	5.66	14.70%	-	-
15	GlaxoSmithKine (GSK) ^[1]	31.46	18.7%	6.90	48.00%	5.28	40.00%	64.52	-24.00%	2.42	-15.00%	5.89	9.00%	12.09	37%
16	Takeda ^[3]	30.60	12.8%	3.73	6.40%	2.41	37.70%	-	-	-	-	4.80	-	*	*	10.80	21.73%
17	Eli Lilly ^[1]	28.54	1.0%	6.81	10.57%	6.24	12.00%	49.49	1.40%	1.85	41.22%	7.19	4.00%	*	*
18	Gilead ^[1]	27.28	-0.1%	7.33	-26.09%	4.57	-26.37%	63.17	-7.04%	0.73	25.73%	4.98	8.17%	*	*	-	-
19	Amgen ^[1]	26.32	1.3%	9.57	25.23%	6.55	11.18%	65.12	6.47%	0.94	6.36%	4.43	-7.99%	24.80	2.07%
20	Boehringer Ingelheim ^[1]	25.90	17.0%	5.12	1.38%	3.41	-6.60%	45.59	4.63%	3.19	5.17%	5.41	22.00%	19.80	20.70%
21	Novo Nordisk ^[1]	25.05	25.7%	10.59	28.00%	7.86	16.27%	34.15	24.03%	1.71	92.06%	3.40	35.31%	*	*
22	Moder- ^[1]	19.26	4.3%	9.42	-29.15%	8.36	-31.47%	25.86	4.82%	0.40	40.85%	3.30	65.49%	18.4	4%	-	-
23	BioNTech ^[1]	18.57	-8.8%	13.56	-17.28%	10.12	-8.34%	24.97	47.05%	-	-	1.65	61.93%	-	-	-	-
24	Viatris ^[1]	16.26	-9.1%	-	-	-	-	-	-	0.41	-11.00%	-	-	16.22	-9%	5.78	-9%
25	Baxter Pharma ^[1]	15.11	18.2%	1.94	13.63%	2.42	86.95%	28.29	-15.61%	0.679	-8.61%	0.61	13.30%	*	*	-	-
26	Teva ^[1]	14.93	-6.0%	2.10	22.32%	2.35	464.27%	44.01	-7.68%	0.55	-2.49%	0.84	-13.34%	*	*	-	-
27	Regeneron ^[1]	12.17	-24.3%	4.74	-47.03%	4.34	-46.28%	29.21	14.86%	0.59	6.92%	3.59	25.61%	6.89	-43.10%	-	-
28	Astellas ^[3]	11.54	17.2%	1.01	-14.60%	0.75	-20.45%	18.67	5.32%	0.64	35.39%	2.10	12.20%	*	*	-	-
29	CSL ^[4]	10.56	2.4%	2.93	-6.50%	2.25	-5.10%	28.35	56.10%	1.25	-25.20%	1.16	15.50%	8.60	2%	3.60	-3.30%
30	Biogen ^[1]	10.17	-7.4%	3.59	105.81%	3.05	95.80%	24.55	2.83%	0.24	-	2.23	-10.80%	*	*	-	-
31	Daiichi Sankyo ^[3]	9.72	22.0%	0.92	65.00%	0.83	63.00%	19.07	13.00%	-	-	2.60	31.00%	9.72	22.40%	-	-
32	Chugai ^[1]	9.58	26.0%	4.05	26.40%	2.85	23.60%	14.21	21.52%	0.47	-14.17%	1.14	4.11%	7.90	29.45%	-	-
33	Vertex Pharma ^[1]	8.93	17.9%	4.31	54.83%	3.32	41.84%	18.15	35.13%	0.32	-5.80%	2.54	31.09%	*	*	-	-
34	Bausch Health ^[1]	8.12	-3.7%	0.45	0.89%	0.23	-76.27%	25.69	-12.04%	0.30	-25.92%	0.53	13.76%	*	*	0.23	53.20%
35	Zoetis ^[1]	8.08	3.9%	-	-	2.11	3.78%	-	-	-	-	0.54	6.10%	*	*	-	-
36	Otsuka ^[1]	6.54	1.1%	0.42	-1.90%	0.31	0.10%	3.97	7.56%	0.06	-8.79%	0.01	16.40%	*	*	-	-
37	Grifols ^[1]	6.50	22.9%	0.86	35.39%	0.29	2.19%	23.10	11.96%	0.32	6.00%	0.39	1.76%	*	*	1.31	27.00%
38	Fosun Pharma ^[1]	6.35	13.0%	0.66	-24.00%	0.57	-21.00%	7.84	12.00%	0.84	23.00%	0.62	12.00%	4.45	6.68%	1.17	-9%
39	UCB ^[1]	5.92	-4.5%	-	-54.00%	0.45	-61.00%	17.02	11.67%	0.40	-25.00%	1.79	3.00%	5.51	-6%	1.35	-23%
40	Eisai ^[3]	5.66	-1.6%	0.30	-25.51%	0.43	24.32%	9.60	1.94%	0.17	-21.23%	1.31	0.73%	5.15	11.96%	-	-
41	Zhifei Bio ^[1]	5.55	24.8%	-	-	1.09	-26.15%	5.51	26.48%	-	-	0.12	54.46%	0.02	-44.21%	-	-
42	Servier ^[5]	5.23	9.8%	0.47	76.00%	0.21	287.00%	-	-	-	-	-	-	*	*	0.92	34.60%
43	Sun Pharma ^[2]	4.79	15.3%	1.09	27.34%	0.40	12.70%	8.45	3.15%	4.02	7.44%	0.27	3.23%	1.54	23%	1.22	23.60%
44	CSPC Pharma ^[1]	4.49	11.0%	1.10	10.74%	0.90	9.56%	4.59	17.94%	0.24	0.50%	0.58	16.14%	*	*	-	-
45	Elanco ^[1]	4.41	-7.0%	0.07	-87.00%	0.08	-84.00%	15.49	-5.99%	0.14	8.73%	0.32	-13.00%	*	*	0.85	128%
46	Dainippon Sumitomo ^[3]	4.22	-0.8%	0.59	27.80%	0.74	138.21%	8.62	-13.25%	0.55	-9.45%	1.00	38.94%	3.88	-1.82%	-	-
47	Sino Biopharma ^[1]	4.17	7.1%	0.84	-68.89%	0.73	-69.89%	9.29	5.82%	0.26	-	0.62	15.66%	*	*	-	-
48	STADA ^[1]	4.07	16.9%	0.61	24.95%	0.38	34.61%	6.17	-0.03%	0.30	-28.29%	0.10	9.36%	*	*	0.94	17%
49	Galderma ^[1]	3.76	13.9%	-	-	-	-	-	-	-	-	-	-	-	-	0.79	14.50%
50	Jazz Pharma ^[1]	3.66	18.3%	0.07	-61.52%	0.22	-32.03%	10.84	-11.90%	0.03	5.08%	0.59	16.75%	3.64	18%	-	-
51	Horizon Therapeutics ^[1]	3.63	12.0%	0.62	14.00%	0.52	-2.00%	9.11	5.00%	0.06	-16.00%	0.44	27.00%	*	*	1.09	18%
52	Ono ^[3]	3.40	23.8%	1.08	37.57%	0.86	39.94%	6.71	19.38%	0.13	-1.13%	0.72	25.65%	2.24	19.92%	-	-
53	Incyte ^[1]	3.39	13.7%	0.58	-1.08%	0.34	-64.09%	5.84	18.40%	0.08	-57.00%	1.59	8.76%	*	*	-	-
54	Ipsen ^[1]	3.24	14.4%	1.20	"13.5%	"	0.94	"17.9%	"	-	-	-	-	0.48	4.92%	*	*	-	-
55	Shionogi ^[3]	3.24	27.3%	1.13	35.07%	1.40	62.64%	9.97	14.01%	0.09	-54.71%	0.78	40.27%	*	*	-	-
56	Hengrui Medicine ^[1]	3.08	-17.9%	0.44	-19.92%	0.57	-13.77%	6.14	7.87%	-	-	0.92	-	*	*	-	-
57	Octapharma ^[1]	3.06	14.0%	0.56	14.00%	0.48	2.00%	4.83	9.00%	0.22	9.00%	0.08	-3.00%	*	*	-	-
58	Kyowa Kirin ^[1]	3.03	13.1%	0.66	31.99%	0.41	2.34%	7.14	1.95%	0.24	38.72%	0.48	9.04%	*	*	0.66	8.27%
59	Chiesi ^[1]	2.95	13.6%	-	-	-	-	-	-	-	-	-	-	-	-	-	7%
60	Pierre Fabre ^[1]	2.90	8.0%	-	-	-	-	-	-	-	-	0.18	25.74%	*	-	-	-
61	Aurobindo ^[2]	2.84	-5.3%	0.41	-54.07%	0.32	-50.37%	4.10	0.20%	0.02	55.88%	0.19	4.76%	*	*	0.53	-17.75%
62	Cipla ^[2]	2.63	13.6%	0.42	6.18%	0.31	6.62%	3.28	7.74%	0.07	-13.65%	0.13	24.63%	*	*	0.55	6.39%
63	Dr. Reddy's ^[2]	2.59	13.0%	0.36	21.40%	0.29	37.00%	3.59	11.74%	-	-	0.21	5.69%	*	*	0.62	8.47%
64	Lundbeck ^[1]	2.58	12.0%	0.40	41.89%	0.27	45.37%	5.30	8.08%	-	-	0.53	-1.80%	*	*	0.66	25.23%
65	Hikma ^[1]	2.52	-1.4%	0.28	-51.55%	0.19	-54.52%	4.47	2.26%	0.138	-4.83%	0.14	0.70%	-	-	-	-
66	Ferring ^[1]	2.44	5.3%	0.25	-35.41%	0.19	-39.38%	3.38	5.37%	0.13	88.85%	0.37	11.19%	0.00	5.23%	0.39	-26.33%
67	Endo Inter-tio-l ^[1]	2.32	-22.5%	2.41	24695.99%	2.97	383.67%	5.76	-34.33%	-	-	0.13	3.72%	*	*	-	-
68	Royalty Pharma ^[1]	2.24	-2.3%	0.31	-78.55%	0.04	-93.06%	16.81	-4.01%	1.03	-44.97%	0.18	-11.50%	*	*	2.57	32%
69	Angelini ^[1]	2.20	15.0%	0.04	2600.89%	0.09	-17.19%	4.81	4.84%	-	-	-	-	-	-	0.27	31.79%
70	Santen ^[3]	2.12	4.8％	0.02	-91.39%	0.11	-44.89%	3.20	-8.43%	0.16	-4.95%	0.22	7.28%	*	*	0.38	-7.30%
71	BioMarin ^[1]	2.10	13.5%	0.15	81.64%	0.14	120.91%	6.38	6.17%	-	-	0.65	3.31%	2.04	14.50%	-	-
72	Genmab ^[1]	2.07	72.1%	0.90	110.64%	0.78	83.58%	4.29	22.95%	0.39	187.30%	0.79	33.03%	1.65	67.29%	-	-
73	Recordati ^[1]	1.99	17.3%	0.47	-10.80%	0.34	-19.10%	4.29	41.99%	0.03	9.31%	0.24	32.50%	1.94	17.80%	0.72	11.70%
74	Lupin ^[2]	1.99	8.2%	-	-	0.18	25.61%	2.64	-7.58%	0.11	33.57%	0.17	-2.10%	1.96	8.50%	0.28	18.10%
75	Seattle Genetics ^[1]	1.96	24.7%	0.60	-10.86%	0.61	-9.51%	3.67	-1.21%	-	-	1.34	9.42%	*	*	-	-
76	Sobi ^[1]	1.86	21.0%	0.38	2.14%	0.26	-1.53%	5.21	7.88%	-	-	0.23	18.05%	*	*	0.62	8.55%
77	Grünenthal ^[1]	1.82	13.0%	-	-	-	-	-	-	-	-	-	-	-	-	0.47	18%
78	Celltrion ^[1]	1.80	20.6%	0.51	-13.00%	0.42	-9.70%	4.69	4.55%	-	-	0.11	11.09%	*	*	-	-
79	Exelixis ^[1]	1.61	12.3%	0.20	-29.71	0.18	-21.11%	-	-	-	-	0.89	28.56%	*	*	-	-
80	LEO Pharma ^[1]	1.51	6.9%	0.47	-20.33%	0.58	-15.57%	3.25	-3.22%	0.67	5.49%	0.35	-19.10%	*	*	0.18	-27.61%
81	Neurocrine ^[1]	1.49	31.3%	0.25	142.93%	0.15	72.43%	2.37	14.29%	0.02	-29.49%	0.46	41.36%	1.44	32.18%	-	-
82	Orion ^[1]	1.44	28.8%	0.47	80.68%	0.37	80.34%	1.61	34.96%	0.12	28.34%	0.15	15.38%	*	*	0.52	68.49%
83	BeiGene ^[1]	1.42	20.4%	1.79	24.39%	2.00	37.45%	6.38	-25.26%	0.33	23.77%	1.64	12.42%	1.25	97.90%	-	-
84	Hansoh Pharma ^[1]	1.36	-5.6%	0.43	-10.66%	0.37	-4.76%	4.35	10.46%	0.05	-	0.25	-5.77%	*	*	-	-
85	Emergent BioSolutions ^[1]	1.12	-37.5%	0.17	-51.02%	0.22	-3.07%	3.17	7.02%	-	-	0.19	-17.52%	0.97	-6%	-	-
86	Torrent Pharma ^[2]	1.05	8.0%	0.21	12.08%	0.09	-37.92%	1.59	-6.93%	0.02	-39.56%	0.06	4%	*	*	0.32	10%
87	Alnylam ^[1]	1.04	22.9%	0.79	10.78%	1.13	32.64%	3.55	-2.66%	0.07	-5.63%	0.88	11.47%	0.89	35.07%	-	-
88	Biocon ^[2]	1.02	13.5%	0.13	4%	0.09	-9%	2.47	10.11%	0.21	11.93%	0.07	8%	*	*	0.26	14%
89	Kedrion ^[1]	0.95	34.3%	0.14	157.70%	0.13	962.90%	2.51	57.25%	0.08	-18.05%	0.03	13.90%	*	*	0.23	15%
90	Sarepta Therapeutics ^[1]	0.93	32.9%	0.54	16.64%	0.70	67.99%	3.13	-0.62%	-	-	0.88	13.73%	0.84	37.78%	-	-
91	Innovent Biologics ^[1]	0.66	6.7%	0.44	14.08%	0.32	-20.14%	2.55	8.28%	-	-	0.42	23.63%	0.60	-	-	-
92	Ionis ^[1]	0.59	-27.5%	0.41	1258.88%	0.27	843.18%	2.53	-2.98%	-	-	0.83	29.48%	*	*	-	-
93	argenx ^[1]	0.45	-17.0%	0.72	107.00%	0.71	74.00%	3.13	9.96%	-	-	0.66	14.00%	0.40	-	-	-
94	Gan& Lee Pharma ^[1]	0.25	-52.6%	0.08	-66.52%	0.06	-69.75%	1.54	-2.27%	-	-	0.08	18.52%	*	*	-	-
95	SK Biopharma ^[1]	0.19	-41.2%	0.10	38.04%	0.11	115.02%	0.52	3.20%	-	-	-	-	*	*	-	-
96	CanSino Biologics ^[1]	0.15	-76.0%	0.20	-28.40%	0.14	-49.41%	1.66	-3.41%	0.08	76.85%	0.11	-11.43%	*	*	-	-
97	CureVac ^[1]	0.07	-34.6%	0.27	-39.49%	0.0	50.00%	-	-	-	-	0.07	65.19%	-	-	-	-
98	Roivant Sciences	0.06	132.3%	1.35	26.22%	0.85	4.45%	2.59	-0.18%	0.02	200.31%	0.48	104.13%	*	*	-	-
99	Ascendis Pharma ^[1]	0.05	557.9%	0.60	24.35%	0.63	52.04%	1.17	0.44%	-	-	0.41	28.31%	*	*	-	-
100	Mirati Therapeutics ^[1]	0.01	-82.7%	0.76	32.52%	0.74	27.34%	1.20	-24.30%	-	-	0.53	4.53%	-	-	-	-

^[1] FY22 Ending December 31' 22
^[2] FY22 Ending March 31' 22
^[3] FY22 Ending March 31' 23
^[4] FY22 Ending 30 June ' 22
^[5] FY22 Ending 30 September ' 22
^[*] Net sales is equlivalent to net pharmaceutical sales

The pharmaceutical industry is the first and only industry that comes to mind when discussing a sector that operates around-the-clock notwithstanding global crises. In 2022, the pharmaceutical market across the world remained the focal point of public and medical attention, largely driven by the COVID-19 pandemic. The crisis accentuated the medical sector's crucial role in global health and expedited various trends such as vaccine development, enhanced R&D, digital transformation, and personalized medicine. Branded Pharma Companies like Pfizer, Johnson & Johnson, and Roche were in the limelight for their groundbreaking work in COVID-19 vaccines, developed and distributed at an unprecedented scale and speed. This showcased the pharmaceutical industry's capacity for revolution and its ability to mobilize resources in times of urgent global need.

While the pandemic continued to be a major focus, the industry also advanced in other therapeutic areas. Significant investments were made in research and development for oncology, cardiovascular diseases, and rare genetic disorders. Additionally, emerging markets became more and more significant in the world of pharmaceuticals. Countries like, China and India, not only served as significant manufacturing hubs but also as growing markets for pharmaceutical products. These nations have been investing heavily in biotechnology and pharmaceutical R&D, although they still face challenges related to intellectual property rights and regulatory compliance.

Digitization was another key trend shaping the industry. Pharmaceutical companies started leveraging data analytics and artificial intelligence for drug discovery, clinical trials, and market research. These technologies helped in shortening the drug development cycle and made it more cost-efficient. However, the industry also faced its fair share of challenges. More specifically, regulatory scrutiny of drug safety and effectiveness grew globally. The impending "patent cliff," where many popular drugs will no longer be protected by patents, created a serious problem for revenue streams. Governments and advocacy organizations were also increasing their pressure for more open pricing structures and simpler access to crucial medications.

In conclusion, the pharmaceutical sector in 2022 was a challenging yet exhilarating field, characterized by rapid advancements. The year served as a monument to the sector's determination, as well as inventiveness, and crucial function in solving global health concerns.

Therefore, by comparing the financial performance of the global pharmaceutical market in 2022 to 2021, ChemAnalyst attempts to highlight the impact of market uncertainties and challenges on this industry through this study.

Top Performers

ChemAnalyst has conducted a comprehensive analysis and ranking of companies based on their performance, considering key indicators such as Revenue, Business Operating Income, Net Income, Total assets, and R&D expenditure in 2022 compared to 2021.

Top 10 Companies by Revenue

While Pfizer led supreme with its magnificent revenue of $100.33 billion, the likes of Janssen/Johnson & Johnson, Roche, Merck, and other industry giants walked a similar path. Not too far behind, Janssen/ Johnson & Johnson charted its course with a remarkable revenue of $94.94 billion. Roche, Merck, and AbbVie too left indelible marks on the sands of time, with revenues soaring beyond $58 billion each. The ongoing Covid-19 pandemic propelled pharmaceutical company Pfizer's earnings to exceed $100 billion in 2022, over $57 billion of which was driven by their vaccine and antiviral drug Paxlovid. The combined sales of Pfizer's Covid vaccine and antiviral medication brought in more money in 2018 than its overall sales did in 2019, before the pandemic turned into a worldwide calamity that claimed more than 6.8 million lives and upended global markets. It's doubtful that those outcomes will occur again this year. As the world recovers from the pandemic and the market for Pfizer's best-selling Covid medications decreases, the company expects its revenue to fall by more than 30% to between $67 billion and $71 billion in 2023.

Top 10 Companies by Business Operating Income

The term "operating profit" took on a whole new meaning in the pharmaceutical industry in 2022, with some companies setting exceptional benchmarks. Leading this category was Pfizer, whose business operating income stood at a staggering $31.40 billion in FY2022. This performance highlighted the company's expertise at not just generating revenue but also converting it into meaningful profit. Trailing behind, yet impressive in its own right, was Roche with $21.73 billion. The company demonstrated its ability to manage its operations efficiently, thereby securing a healthy bottom line. With an operating income of $24.04 billion, Janssen/ Johnson & Johnson took third place. The multinational Swiss company demonstrated that a balanced strategy to revenue and profit have led to positive outcomes. In this area, too, Merck and AbbVie remained fierce rivals, reporting operating earnings of $16.4 billion and $18.1 billion, respectively. The year 2022 served as a witness to the operational efficiencies of these companies, setting the stage for what promises to be an intriguing 2023 in terms of profitability.

Top 10 Companies by Net Income

In the pharmaceutical industry, a company's net income is frequently regarded as the gold standard for gauging its financial stability. And in 2022, a few businesses stood out in this regard, going beyond only generating revenue to securing significant profits. Pfizer once again held sway thanks to a $31.37 billion net income. This impressive statistic demonstrates the company's ability to convert sales into large profits, further solidifying its position as the market leader. Following closely was Janssen/ Johnson & Johnson, with a net income of $17.94 billion. The figure not only places the company in a strong second position but also underlines its balanced approach to both revenue and profit. Merck and AbbVie, the industry’s closely matched rivals, reported net incomes of $14.51 billion and $11.83 billion, respectively. In year 2022, both Merck and AbbVie have demonstrated robust net income figures, reflecting their prominence in the pharmaceutical industry. Merck's net income has steadily risen due to its diverse portfolio of drugs and vaccines, with innovations like Keytruda driving substantial revenue. In contrast, AbbVie's net income growth can be attributed to its blockbuster drug, Humira, along with strategic acquisitions like Allergan. These impressive net income results highlight their drive and capacity for innovation in the cutthroat healthcare industry, indicating that they will continue to make contributions to medical progress.

Top 10 Companies by Total Assets

In the monarchy of financial stability, assets serve as a significant indicator. And in 2022, some businesses in the pharmaceutical sector accumulated sizable assets, strengthening their market positions. Pfizer, consistent with its performance in other categories, topped the list with total assets amounting to $197.21 billion. This formidable asset base further cements Pfizer's leadership position in the industry. Next in line was Janssen/ Johnson & Johnson, boasting assets totalling $187.37 billion. The company’s significant asset base stands as a testament to its financial stability and long-term planning. AbbVie surprised many by taking the third spot with assets worth $138.80 billion. This robust asset base shows that AbbVie is more than just a revenue and profit generator; it's a well-rounded player in the pharmaceutical sector. Merck followed with assets amounting to $35.72 billion. Though lower than the top three, this figure still demonstrates Merck's solid financial grounding. Further down the list, Bristol-Myers Squibb and Sanofi managed assets of $46.15 billion and $46.12 billion, respectively. These figures underline their balanced approach to financial management, a key to long-term sustainability. The year 2022 set the stage for an interesting 2023, as companies will likely focus not just on revenue and profit, but also on asset accumulation and management.

Top 10 Companies by R&D expenditure

Research and Development (R&D) expenses are a key indicator of a company's commitment to innovation and future growth. In 2022, several pharmaceutical giants demonstrated their dedication to pushing the boundaries of science and medicine. Leading the charge in this arena was Roche, with a colossal investment of $15.23 billion in R&D. This commitment reflects Roche's focus on innovation and its pursuit of breakthroughs in healthcare. In 2022, Roche experienced great success with the ophthalmic drug Vabysmo, a cutting-edge treatment for certain serious eye disorders. This innovative eye treatment was introduced in the beginning of 2022, with many people already having access to it. Within a short period of time, Vabysmo rose to prominence as one of the major development drivers. Another important drug for blood cancer were another success from the R&D division. For those suffering from a specific type of follicular lymphoma, Lunsumio offered hope. A potential new strategy for treating blood cancer emerged with Roche's new immunotherapy. After Roche, Janssen/ Johnson & Johnson took the second place, with an R&D expenditure of $14.6 B. This significant investment showcases the company's commitment to research, further solidifying its position as a leader in the pharmaceutical industry. Merck followed closely, directing $13.548 billion towards R&D, signalling its intention to remain at the forefront of medical innovation. Pfizer, although leading in other financial parameters, invested $11.42 billion in R&D. The figure might be less than some of its peers, but it still underlines Pfizer's balanced approach to both current profitability and future innovation.

In conclusion, the R&D spending for 2022 shows the pharmaceutical industry's dedication to innovation and development, opening up promising possibilities for improvements in healthcare and medicine in 2023 and beyond.

Research Methodology

A thorough list of the largest pharmaceutical manufacturing companies in the world was compiled, and their annual reports for the year 2022 were analysed through consolidated balance sheets. The primary factor used to determine the order of the companies was their net revenue or sales throughout the year 2022. A number of companies, however, published their financial reports for the fiscal year that ended in 2022 or March 2023. The list also featured businesses that operated various lines of businesses, such as manufacturing chemicals or medical equipment. But for the ranking with a separate category, their pharmaceutical drugs segment was primarily taken into account.

The ranking was determined by the performance's percentage improvement over the previous year (2021). However, Pharmaceutical companies that faced losses during the previous year were skipped, as an improvement shown in percentage change would give a wrong indication of their performance. Only significant financial factors were considered, including sales or revenue, EBIT (earnings before interest and taxes)/Business Operating Income, R&D (research and development) expenses, capital expenditures (CAPEX), and EBITDA (earnings before interest, taxes, depreciation, and amortization). The percentage difference between these financial variables and the prior year (2021) was calculated. Discovering the actual performance of the companies can be accomplished by analysing these monetary indicators. However, some important financial indicators had to be skipped due to different approaches by some companies in demonstrating their financials, as they were not clearly mentioned in their annual press releases.

Furthermore, all currencies were converted into USD, based on the conversion rate on December 31, 2022, in order to maintain a level playing field for all the companies.

Disclaimer

The information provided in this ranking is intended to be informative and should not be relied upon as the sole factor in making any financial decisions. It is important to note that each country may have its own unique financial reporting regulations and that companies may use various methods to present their financial performance. Therefore, discrepancies in reported values may occur. While every effort has been made to generate this ranking using the most appropriate and relevant approach, any suggestions or feedback to improve its accuracy are welcome.